A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
Completed · Phase 3 · NCT04537923
Conditions: Type 2 Diabetes
At a glance
- Research payments reported, 2025
- $425
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 1,428
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Tirzepatide (drug), Insulin Lispro (U100) (drug)
- Dates
- Started 2020-10-19; completion 2022-11-01
- Results posted
- Yes
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or without metformin.
From ClinicalTrials.gov, last updated 2023-11-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $425 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Iowa Diabetes and Endocrinology Rsrch Cntr $425
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.